GB2392093B - Pharmaceutical formulations - Google Patents

Pharmaceutical formulations

Info

Publication number
GB2392093B
GB2392093B GB0218930A GB0218930A GB2392093B GB 2392093 B GB2392093 B GB 2392093B GB 0218930 A GB0218930 A GB 0218930A GB 0218930 A GB0218930 A GB 0218930A GB 2392093 B GB2392093 B GB 2392093B
Authority
GB
United Kingdom
Prior art keywords
pharmaceutical formulations
formulations
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
GB0218930A
Other versions
GB2392093A (en
GB0218930D0 (en
Inventor
Brian Anthony Whittle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GW Pharma Ltd
Original Assignee
GW Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GW Pharma Ltd filed Critical GW Pharma Ltd
Priority to GB0218930A priority Critical patent/GB2392093B/en
Publication of GB0218930D0 publication Critical patent/GB0218930D0/en
Priority to ES10180523.2T priority patent/ES2625605T3/en
Priority to PT03787900T priority patent/PT1542657E/en
Priority to EP03787900A priority patent/EP1542657B8/en
Priority to ES03787900T priority patent/ES2377819T3/en
Priority to JP2004528678A priority patent/JP4515908B2/en
Priority to DK03787900.4T priority patent/DK1542657T3/en
Priority to PL375224A priority patent/PL215220B1/en
Priority to PCT/GB2003/003574 priority patent/WO2004016246A1/en
Priority to SI200332107T priority patent/SI1542657T1/en
Priority to CA2454644A priority patent/CA2454644C/en
Priority to EP10180523.2A priority patent/EP2314284B1/en
Priority to AU2003253005A priority patent/AU2003253005B2/en
Priority to CN03824097A priority patent/CN100594897C/en
Priority to PT101805232T priority patent/PT2314284T/en
Priority to MXPA05001567A priority patent/MXPA05001567A/en
Priority to AT03787900T priority patent/ATE533472T1/en
Priority to DK10180523.2T priority patent/DK2314284T3/en
Priority to KR1020057002528A priority patent/KR101008609B1/en
Publication of GB2392093A publication Critical patent/GB2392093A/en
Priority to ZA200501228A priority patent/ZA200501228B/en
Application granted granted Critical
Publication of GB2392093B publication Critical patent/GB2392093B/en
Priority to AU2009202434A priority patent/AU2009202434B2/en
Priority to CY20121100154T priority patent/CY1112523T1/en
Priority to LU92233C priority patent/LU92233I2/en
Priority to FR14C0025C priority patent/FR14C0025I2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
GB0218930A 2002-08-14 2002-08-14 Pharmaceutical formulations Expired - Lifetime GB2392093B (en)

Priority Applications (24)

Application Number Priority Date Filing Date Title
GB0218930A GB2392093B (en) 2002-08-14 2002-08-14 Pharmaceutical formulations
AU2003253005A AU2003253005B2 (en) 2002-08-14 2003-08-14 Cannabinoid liquid formulations for mucosal administration
PT101805232T PT2314284T (en) 2002-08-14 2003-08-14 Cannabinoid liquid formulations for mucosal administration
EP03787900A EP1542657B8 (en) 2002-08-14 2003-08-14 Cannabinoid liquid formulations for mucosal amdinistration
ES03787900T ES2377819T3 (en) 2002-08-14 2003-08-14 Liquid cannabinoid formulations for mucosal administration
JP2004528678A JP4515908B2 (en) 2002-08-14 2003-08-14 Cannabinoid liquid formulation for mucosal administration
DK03787900.4T DK1542657T3 (en) 2002-08-14 2003-08-14 Liquid cannabinoid formulations for administration via a mucosa
PL375224A PL215220B1 (en) 2002-08-14 2003-08-14 Cannabinoid liquid formulations for mucosal amdinistration
PCT/GB2003/003574 WO2004016246A1 (en) 2002-08-14 2003-08-14 Cannabinoid liquid formulations for mucosal amdinistration
SI200332107T SI1542657T1 (en) 2002-08-14 2003-08-14 Cannabinoid liquid formulations for mucosal amdinistration
CA2454644A CA2454644C (en) 2002-08-14 2003-08-14 Cannabinoid liquid formulations for mucosal administration
EP10180523.2A EP2314284B1 (en) 2002-08-14 2003-08-14 Cannabinoid liquid formulations for mucosal administration
ES10180523.2T ES2625605T3 (en) 2002-08-14 2003-08-14 Liquid cannabinoid formulations for administration to the oral mucosa
CN03824097A CN100594897C (en) 2002-08-14 2003-08-14 Cannabinoid liquid formulations for mucosal amdinistration
PT03787900T PT1542657E (en) 2002-08-14 2003-08-14 Cannabinoid liquid formulations for mucosal amdinistration
MXPA05001567A MXPA05001567A (en) 2002-08-14 2003-08-14 Cannabinoid liquid formulations for mucosal amdinistration.
AT03787900T ATE533472T1 (en) 2002-08-14 2003-08-14 LIQUID CANNABINOID FORMULATIONS FOR ADMINISTRATION TO THE MUCOUS MEASURES
DK10180523.2T DK2314284T3 (en) 2002-08-14 2003-08-14 LIQUID CANNABINOID FORMULAS FOR MUSHROAD ADMINISTRATION
KR1020057002528A KR101008609B1 (en) 2002-08-14 2003-08-14 Cannabinoid liquid formulations for mucosal administration
ZA200501228A ZA200501228B (en) 2002-08-14 2005-02-10 Cannabinoid liquid formulations of mucosal administration
AU2009202434A AU2009202434B2 (en) 2002-08-14 2009-06-18 Cannabinoid liquid formulations for mucosal administration
CY20121100154T CY1112523T1 (en) 2002-08-14 2012-02-15 LIQUID COMPOSITIONS OF CANNIVOIDES FOR Mucosal Administration
LU92233C LU92233I2 (en) 2002-08-14 2013-06-26 Sativex and its pharmaceutically acceptable derivatives
FR14C0025C FR14C0025I2 (en) 2002-08-14 2014-03-21 LIQUID PREPARATIONS OF CANNABINOIDS FOR MUCOSAL ADMINISTRATION

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0218930A GB2392093B (en) 2002-08-14 2002-08-14 Pharmaceutical formulations

Publications (3)

Publication Number Publication Date
GB0218930D0 GB0218930D0 (en) 2002-09-25
GB2392093A GB2392093A (en) 2004-02-25
GB2392093B true GB2392093B (en) 2006-03-08

Family

ID=9942325

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0218930A Expired - Lifetime GB2392093B (en) 2002-08-14 2002-08-14 Pharmaceutical formulations

Country Status (3)

Country Link
CN (1) CN100594897C (en)
GB (1) GB2392093B (en)
ZA (1) ZA200501228B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006017892A1 (en) * 2004-08-16 2006-02-23 Northern Sydney And Central Coast Area Health Service Methods for improving cognitive functioning
GB2434312B (en) * 2006-01-18 2011-06-29 Gw Pharma Ltd Cannabinoid-containing plant extracts as neuroprotective agents
FR2906140B1 (en) 2006-09-22 2008-12-05 Philippe Perovitch GALENIC FORM FOR TRANSMUCOSUS ADMINISTRATION OF ACTIVE INGREDIENTS
GB2461681A (en) * 2008-04-17 2010-01-13 Pharmasol Ltd Buprenorphine liquid spray formulation with solvent and antioxidant
GB2450753B (en) * 2007-07-06 2012-07-18 Gw Pharma Ltd New Pharmaceutical formulation
GB2456183A (en) * 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
TWI583374B (en) * 2010-03-30 2017-05-21 Ｇｗ伐瑪有限公司 Use of the phytocannabinoid cannabidivarin (cbdv) in the treatment of epilepsy
GB2491118B (en) * 2011-05-20 2015-12-30 Otsuka Pharma Co Ltd Cannabinoids for use in the treatment of neuropathic pain
GB201111261D0 (en) 2011-07-01 2011-08-17 Gw Pharma Ltd Cannabinoids for use in the treatment of neuro-degenerative diseases or disorders
WO2017208072A2 (en) * 2016-06-02 2017-12-07 Acerus Pharmaceutical Corporation Nasal cannabidiol compositions
CA3010636A1 (en) 2016-06-29 2018-01-04 CannScience Innovations Inc. Decarboxylated cannabis resins, uses thereof and methods of making same
CA2993834A1 (en) * 2017-04-24 2018-10-24 1091665 Bc Ltd. Preparation of a solution of cannabinoids for personal vaping
CN109498606A (en) * 2017-09-15 2019-03-22 汉义生物科技（北京）有限公司 A kind of composition containing cannabidiol and/or cannabidivarin and its application in treatment dysmenorrhea
WO2020121218A2 (en) * 2018-12-11 2020-06-18 Giuseppe Cannazza Extraction method and composition obtained therefrom
CN110038251B (en) * 2019-05-30 2021-07-30 汉义生物科技（北京）有限公司 A method for degrading cannabinoid
CN110200953B (en) * 2019-06-15 2022-02-08 汉义生物科技（北京）有限公司 Use of cannabinoids in the manufacture of a medicament for inhalation administration
JP2023553335A (en) 2020-11-24 2023-12-21 イッサム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム・リミテッド Cannabinoid derivatives and their use in the treatment of inflammation, pain or obesity

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704406A (en) * 1985-06-24 1987-11-03 Klinge Pharma Gmbh Sprayable pharmaceutical composition for topical use
WO2001013886A1 (en) * 1999-08-20 2001-03-01 Roxane Laboratories, Inc. Composition for inhalation comprising delta-9-tetrahydrocannabinol in a semiaqueous solvent

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704406A (en) * 1985-06-24 1987-11-03 Klinge Pharma Gmbh Sprayable pharmaceutical composition for topical use
WO2001013886A1 (en) * 1999-08-20 2001-03-01 Roxane Laboratories, Inc. Composition for inhalation comprising delta-9-tetrahydrocannabinol in a semiaqueous solvent

Also Published As

Publication number Publication date
GB2392093A (en) 2004-02-25
CN1688290A (en) 2005-10-26
GB0218930D0 (en) 2002-09-25
CN100594897C (en) 2010-03-24
ZA200501228B (en) 2006-08-30

Similar Documents

Publication Publication Date Title
GB0210397D0 (en) Pharmaceutical formulations
GB2389530B (en) Pharmaceutical compositions
IL172824A0 (en) Pharmaceutical formulations
GB0302671D0 (en) Pharmaceutical formulations
GB0319041D0 (en) Pharmaceutical Formulations
AU2003291103A8 (en) Pharmaceutical composition
GB2391473B (en) Pharmaceutical compositions
AU2003250372A8 (en) Pharmaceutical composition
GB2392093B (en) Pharmaceutical formulations
HUP0303948A2 (en) Solid orally-dispersible pharmaceutical formulation
GB0302672D0 (en) Pharmaceutical formulations
GB0103638D0 (en) Pharmaceutical formulations
GB0120701D0 (en) Pharmaceutical formulations
GB0121715D0 (en) Pharmaceutical formulations
GB2380129B (en) Pharmaceutical formulations
GB0105560D0 (en) Pharmaceutical formulations
GB0316341D0 (en) Pharmaceutical formulations
GB0213481D0 (en) Pharmaceutical compositions
GB0206505D0 (en) Pharmaceutical combination
PL373409A1 (en) Pharmaceutical combination
GB0225926D0 (en) Pharmaceutical paste formulations
GB0214147D0 (en) Formulations
GB0124455D0 (en) Pharmaceutical formulations
PL370907A1 (en) Pharmaceutical compositions
GB0316335D0 (en) Pharmaceutical formulations

Legal Events

Date Code Title Description
CTFF Supplementary protection certificate filed

Free format text: PRODUCT NAME: SATIVEX OROMUCOSAL SPRAY CONTAINING IN EACH ML 27MG DELTA-9-TETRAHYDROCANNABINOL +25MG CANNABIDIOL; REGISTERED: UK PL 18024/0009 20100616

Spc suppl protection certif: SPC/GB10/049

Filing date: 20101213

732E Amendments to the register in respect of changes of name or changes affecting rights (sect. 32/1977)

Free format text: REGISTERED BETWEEN 20210506 AND 20210512

PE20 Patent expired after termination of 20 years

Expiry date: 20220813

CTFE Supplementary protection certificate entered into force

Free format text: PRODUCT NAME: OROMUCOSAL SPRAY CONTAINING TETRAHYDROCANNABINOL AND CANNABIDIOL; REGISTERED: UK PL 18024/0009 20100616

Spc suppl protection certif: SPC/GB10/049

Filing date: 20101213

Expiry date: 20220814

Extension date: 20250615